Auhtors: Agrawal S, Vamadevan P, Mazibuko N, Bannister R, Swery R, Wilson S PMID: 31316378 PMCID: PMC6610246 DOI: 10.3389/fphar.2019.00681 Abstract In oncology, preclinical and early clinical data increasingly support the use of a number of candidate "non-cancer" drugs in an off-label setting against multiple tumor types. In particular, metabolically targeted drugs show promise as adjuvant [...]

Auhtors: Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, et al. PMID: 29108370 PMCID: PMC5668103 DOI: 10.18632/oncotarget.20168 Abstract Background: In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The Prevalence of Malnutrition in Oncology (PreMiO) study identified malnutrition or its risk among cancer patients [...]

Abstract To gain insight into the commercial changes occurring in the oncology industry, Campbell Alliance initiated the Oncology National Commercial (ONC) study where 75 key industry experts, physicians, payers, and opinion leaders were surveyed. The study revealed an alarming pattern that told us that the oncology space is transforming in such a way that never-before-seen [...]